Groups Try To Block AIDS Drug Patent In India

Law360, New York (June 26, 2008, 12:00 AM EDT) -- A Brazilian AIDS advocacy group and an Indian health charity started legal proceedings on Friday to block U.S. company Gilead Sciences from patenting a key AIDS drug in India.

The Brazilian Interdisciplinary AIDS Association (ABIA) and India's Sahara Center for Residential Care & Rehabilitation said a patent on the AIDS drug tenofovir would restrict generic competition in India and also impact the ability of Brazil to produce and access affordable generic versions of drugs.

Tenofovir disoproxil fumarate is used in a first- and second-line drug regime...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.